KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $26.8 billion.

  • Teva Pharmaceutical Industries' Non-Current Assets rose 10.46% to $26.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $108.3 billion, marking a year-over-year decrease of 694.16%. This contributed to the annual value of $26.8 billion for FY2025, which is 10.46% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Non-Current Assets stood at $26.8 billion for Q4 2025, which was up 10.46% from $27.1 billion recorded in Q3 2025.
  • Teva Pharmaceutical Industries' Non-Current Assets' 5-year high stood at $36.6 billion during Q1 2021, with a 5-year trough of $26.8 billion in Q4 2024.
  • Moreover, its 5-year median value for Non-Current Assets was $31.0 billion (2023), whereas its average is $31.3 billion.
  • In the last 5 years, Teva Pharmaceutical Industries' Non-Current Assets crashed by 1382.85% in 2021 and then increased by 10.46% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Non-Current Assets (Quarter) stood at $35.1 billion in 2021, then decreased by 8.93% to $32.0 billion in 2022, then decreased by 3.02% to $31.0 billion in 2023, then fell by 13.62% to $26.8 billion in 2024, then rose by 0.1% to $26.8 billion in 2025.
  • Its last three reported values are $26.8 billion in Q4 2025, $27.1 billion for Q3 2025, and $27.5 billion during Q2 2025.